Supoxim

Cefpodoxime Proxetil
Antibiotics

Supoxim

Description

Composition:

Supoxim Powder for Suspension: After reconstitution each 5 ml suspension contains Cefpodoxime Proxetil USP equivalent to Cefpodoxime 40 mg.

Pharmacology:

Cefpodoxime Proxetil is an orally administered prodrug that is de-esterified in the intestinal wall to release Cefpodoxime, a third generation cephalosporin. Cefpodoxime is a broad spectrum antibiotic and is active against beta-lactamase producing staphylococci. Cefpodoxime binds with high affinity to penicillin-binding proteins in the bacterial cell wall, thus interfering in peptidoglycan synthesis that provides the cell wall with mechanical stability. Cefpodoxime inhibits the transpeptidase enzyme that performs the final stage in the synthesis of peptidoglycan. As a result, the bacterial cell wall is weakened, and the cell swells and then ruptures.

Indications:

1.Upper respiratory tract infections
2.Lower respiratory tract infections
3.Urinary tract infections including gonorrhoea
4.Skin and soft tissue infections
5.Gynaecological infection
6.Acute otitis media
7.Childhood infection
8.Typhoid fever of children.

Dosage & Administration:

Supoxim should be administered orally with food to enhance absorption. Supoxim suspension may be given without regard to food.

Child :
15 days – 6 months : 4 mg/kg every 12 hours
6 months – 2 years : 40 mg every 12 hours
3 – 8 years : 80 mg every 12 hours
over 9 years : 100 mg every 12 hours

Patients with renal dysfunction: For patients with severe renal impairment (creatinine clearance <30 ml/min) the dosing intervals should be increased to 24 hourly.
Patients with liver cirrhosis: Cefpodoxime proxetil pharmacokinetics in cirrhotic patients are similar to those in healthy subjects. Dose adjustment is not necessary in this population.

Contraindication:

Cefpodoxime is contraindicated in patients with a known allergy to Cefpodoxime Proxetil or to cephalosporin group of antibiotic or any inactive ingredient of the product.

Warning & Precaution:

In patients with transient or persistent reduction in urinary output due to renal insufficiency, the total daily dose of Cefpodoxime should be reduced because high and prolonged serum antibiotic concentration can occur in such individuals following usual doses. Cefpodoxime should be administered with caution to patients receiving concurrent treatment with potent diuretics.

Side Effects:

Diarrhoea and rarely antibiotic-associated colitis, nausea and vomiting, abdominal discomfort, headache; allergic reactions including rashes, pruritus, urticaria, serum sickness-like reactions with rashes, fever and arthralgia, and anaphylaxis, erythemia multiform, toxic epidermal necrolysis reported; disturbances in liver enzymes, transient hepatitis and cholestatic jaundice; etc.

Pregnancy and Lactation:

Use in Pregnancy: Pregnancy category B. This drug should be used during pregnancy only if clearly needed.
Use in Lactation: Cefpodoxime Proxetil is excreted in human milk. Because of the potential for serious reactions in nursing infants, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

Drug interaction:

Antacids: Concomitant administration of high doses of antacids (sodium bicarbonate and aluminium hydroxide) or H2 blockers reduce peak levels and the extent of absorption, though the rate of absorption is not altered by these concomitant medications. Oral anticholinergics delay peak plasma levels, but do not affect the extent of absorption. Probenecid: Probenecid inhibits the excretion of Cefpodoxime. Nephrotoxic drugs: Although nephrotoxicity has not been noted when Cefpodoxime was given alone, close monitoring of renal function is advised when Cefpodoxime is administered concomitantly with compounds of known nephrotoxic potential.

Packing:

Supoxim Powder for Suspension: Each bottle contains powder for the reconstitution of 50 ml/100 ml suspension.